Table 2.
Active and recruiting clinical trials using medical therapeutic approaches for schwannoma.
| ClinicalTrials.Gov Identifier | ID | RP | EE | Age | TS |
|---|---|---|---|---|---|
| NCT01083966 | 8, 2011 | Lenox Hill Brain Tumor Center | 30 | ≥18 | Superselective intraarterial intracranial infusion of bevacizumab |
| NCT04283669 | 2, 2020 | University of Alabama at Birmingham | 19 | ≥6 | Crizotinib |
| NCT03079999 | 6, 2018 | Massachusetts Eye and Ear Infirmary | 300 | ≥12 | Aspirin |
| NCT02282917 | 9, 2015 | Massachusetts Eye and Ear | 5 | ≥18 | AR-42 (OSU-HDAC42) |
| NCT01345136 | 7, 2015 | University of California | 4 | 16–65 | Everolimus |
| NCT03095248 | 5, 2017 | Children’s Hospital Medical Center | 34 | 3–45 | Selumetinib |
| NCT04163419 | 4, 2020 | Massachusetts General Hospital | 46 | ≥18 | Tanezumab |
ER, estimated enrollment; ID, initiation date; RP, responsible party; TS, treatment strategy.